CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05467891
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:00.405427+00:00
- Published At
- 2026-04-08T00:00:00+00:00
- Record Updated At
- 2026-04-08
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Locoregional Recurrence", "Hormone Receptor-positive Breast Cancer", "HER2-negative Breast Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-08"- protocolSection.identificationModule.nctId
"NCT05467891"- protocolSection.identificationModule.officialTitle
"A Phase II Study of Ribociclib And Endocrine Treatment of Physician\u0027s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.